Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03684109 · ClinicalTrials.gov registry record · NA

Non-invasive Glioma Characterization Through Molecular Imaging

A NA study of Glioma and Brain Tumor, sponsored by University of Miami.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT03684109 is a NA study of Glioma and Brain Tumor that is actively recruiting participants, run by University of Miami. The registered enrollment target is 30 participants, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03684109, a NA study of Glioma and Brain Tumor, is actively recruiting participants, sponsored by University of Miami.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

MRI-based sequences can provide non-invasive quantification of intratumoral 2-hydroxyglutarate (2HG) distribution and tumor cellularity in human gliomas and help guide the development of novel glioma therapies.

Interventions

  • DEVICE 3T MRI Scanner

Study Locations (1)

Florida

  • University of Miami - Miami

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2019-01-25
Est. Completion 2026-01-31
Phase NA

Sponsor

University of Miami

721 total trials

What the Registry Record Tells You About NCT03684109

The ClinicalTrials.gov registry entry for NCT03684109 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 210-participant average among 87 other Glioma trials with a reported enrollment target (86% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Glioma appearing as the primary indexed condition, and to 1 intervention - of which 3T MRI Scanner is the first listed.

NCT03684109 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT03684109 about?

NCT03684109 is a clinical study titled "Non-invasive Glioma Characterization Through Molecular Imaging". MRI-based sequences can provide non-invasive quantification of intratumoral 2-hydroxyglutarate (2HG) distribution and tumor cellularity in human gliomas and help guide the development of novel glioma therapies.

What is the current status of trial NCT03684109?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2019-01-25. Estimated completion is 2026-01-31.

What conditions does trial NCT03684109 study?

This clinical trial studies the following conditions: Glioma, Brain Tumor, Malignant Glioma, Primary Brain Tumor, Malignant Primary Brain Tumor.

What interventions are being tested in trial NCT03684109?

The interventions under investigation include: 3T MRI Scanner (DEVICE).

Who is sponsoring clinical trial NCT03684109?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03684109 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glioma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.